Steele CW, Gill NAK, Jamieson NB, Carter CR. Targeting inflammation in pancreatic cancer: Clinical translation. World J Gastrointest Oncol 2016; 8(4): 380-388 [PMID: 27096033 DOI: 10.4251/wjgo.v8.i4.380]
Corresponding Author of This Article
Colin William Steele, MD, Department of Pancreaticobiliary Surgery, Glasgow Royal Infirmary, Queen Elizabeth Building, Glasgow G4 0SF, United Kingdom. cwsteele@hotmail.co.uk
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Apr 15, 2016; 8(4): 380-388 Published online Apr 15, 2016. doi: 10.4251/wjgo.v8.i4.380
Targeting inflammation in pancreatic cancer: Clinical translation
Colin William Steele, Nina Angharad Kaur Gill, Nigel Balfour Jamieson, Christopher Ross Carter
Colin William Steele, Nigel Balfour Jamieson, Christopher Ross Carter, Department of Pancreaticobiliary Surgery, Glasgow Royal Infirmary, Glasgow G4 0SF, United Kingdom
Nina Angharad Kaur Gill, Department of General Surgery, South Glasgow University Hospital, Glasgow G51 4TF, United Kingdom
Author contributions: Steele CW drafted this review; Kaur Gill NA contributed the literature review and table; Jamieson NB and Carter CR edited the final manuscript.
Conflict-of-interest statement: We have no conflicts of interest to disclose.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Colin William Steele, MD, Department of Pancreaticobiliary Surgery, Glasgow Royal Infirmary, Queen Elizabeth Building, Glasgow G4 0SF, United Kingdom. cwsteele@hotmail.co.uk
Telephone: +44-0141-2114000
Received: November 29, 2015 Peer-review started: November 30, 2015 First decision: December 28, 2015 Revised: January 5, 2016 Accepted: February 14, 2016 Article in press: February 16, 2016 Published online: April 15, 2016
Core Tip
Core tip: Many advances have been made in preclinical assessment of therapies in pancreatic cancer. Here we review the successes and failures of translation to clinical trial of therapies targeting the pancreatic cancer microenvironment. Using data from preclinical trials we expose opportunities for further clinical trial within pancreatic cancer. We focus on therapies that modulate the immune response to pancreatic cancer, stromally active therapies and therapies targeting inflammatory signal transduction that are key in pancreatic cancer progression. We provide experimental results that have led to clinical trial and those findings that may be exploited in future. We attempt to rationalize the failure of certain therapies to translate to clinical practice and provide a realistic overview of why at present tumor microenvironment targeted therapies are not licensed in pancreatic cancer.
